Man Group
AVTX icon

Man Group’s Avalo Therapeutics AVTX Stock Holding History

Man Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Sell
36,876
-9,677
-21% -$153K ﹤0.01% 1976
2026
Q1 		$695K Buy
+46,553
New +$728K ﹤0.01% 1963

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Man Group's AVTX Position: Q2 2026 in Review

Man Group reduced its Avalo Therapeutics (AVTX) stake by 21% in Q2 2026, selling an estimated $153K and leaving 36,876 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

Man Group first reported a position in AVTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $695K in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Man Group held 36,876 shares of Avalo Therapeutics worth $681K as of Q2 2026.
  • Man Group sold 9,677 Avalo Therapeutics shares in Q2 2026, an estimated $153K.
  • Avalo Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1976 holding.
  • Man Group first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Man Group's Avalo Therapeutics position peaked at $695K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.